Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)

Summary

To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating patients with the diagnosis of advanced Non-Small-Lung-Cancer

Timeline

Start

2008-11

Primary completion

2010-05

Completion

2010-06

Outcome

Outcome not reported

Stopped (Enrollment): “The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both treatment arms.”

Drugs

Indications